NANOBIOTIX signs non-dilutive financing agreement

Expands the Company cash visibility beyond 2019

30-Jul-2018 - NANOBIOTIX, announced that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities. The financing agreement will allow the Company to borrow up to 40 M€ through loan over the coming five years ...

Nanobiotix reports positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3

11-Jun-2015 - Nanobiotix announced positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial. Intermediate results show the feasibility of the injection of NBTXR3 and a good safety profile of the product for this indication Good safety ...

Nanobiotix Appoints Bernd Muehlenweg as a Member of the Executive Board

26-Apr-2012 - Nanobiotix announced it has appointed Dr. Bernd Muehlenweg, currently “Head of Business Development” as a member of the Executive Board in support of the future growth of Nanobiotix.Bernd Mühlenweg joined Nanobiotix in 2011 as Head of Business Development. From 2001 to 2011, he had been Director ...

Nanobiotix Starts Clinical Trial with Lead Product NBTXR3

A Completely New Cancer Treatment to Be Tested in Patients with Soft Tissue Sarcoma

15-Sep-2011 - Nanobiotix announced that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.27 patients diagnosed with soft tissue sarcoma will be enrolled in the Phase I study and will receive NBTXR3 as an intra-tumoral ...

Nanobiotix Announces Issue of European Patent Protecting Its nanoXray(TM) Anticancer Platform

25-Sep-2008 - Nanobiotix, an emerging nanomedicine company focused on cancer therapy, announced today that the European Patent Office (EPO) has issued Patent No. 1744789 to the Company, related to its “novel activable particles that can be used in the health sector.” More specifically, the patent protects ...